with advanced chronic kidney disease, particularly ones on dialysis, and Prolia. The FDA reviewed 25 cases between July 2010 through May 2021 during the investigation. Boxed warnings are the strictest
impending threat of generics, Novartis sued the FDA over its green light of MSN’s generic Entresto, alleging that it “inappropriately rewrites Entresto’s approved indication” and omits key safety data
total 1 pages, 2 items